Rezolute (RZLT) Liabilities and Shareholders Equity (2011 - 2026)
Rezolute recorded quarterly Liabilities and Shareholders Equity of $125.5 million in Q1 2026, down 9.5% quarter-over-quarter from $138.6 million in Q4 2025, and up 32.43% year-over-year from $94.7 million in Q1 2025.
Rezolute's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $125.5 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 32.43% year-over-year to $125.5 million; the TTM figure through Mar 2026 stood at $598.2 million (up 29.24% YoY), while the FY2025 annual figure was $175.5 million, up 32.21% from the prior year.
- Liabilities and Shareholders Equity came in at $125.5 million for Q1 2026 at Rezolute, down from $138.6 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $175.5 million in Q2 2025 to a low of $69.6 million in Q1 2022.
- A 5-year average of $126.5 million and a median of $125.5 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity surged 302.45% in 2022 and sank 34.62% in 2024, its largest moves.
- Rezolute's Liabilities and Shareholders Equity stood at $150.2 million in 2022, then tumbled by 31.99% to $102.1 million in 2023, then advanced by 9.65% to $112.0 million in 2024, then rose by 23.77% to $138.6 million in 2025, then slipped by 9.5% to $125.5 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $125.5 million, $138.6 million, and $158.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 125.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125.46 Mn |
| Dec 31, 2025 | 138.63 Mn |
| Sep 30, 2025 | 158.66 Mn |
| Jun 30, 2025 | 175.49 Mn |
| Mar 31, 2025 | 94.74 Mn |
| Dec 31, 2024 | 112.01 Mn |
| Sep 30, 2024 | 123.41 Mn |
| Jun 30, 2024 | 132.74 Mn |
| Mar 31, 2024 | 87.74 Mn |
| Dec 31, 2023 | 102.15 Mn |
| Sep 30, 2023 | 113.00 Mn |
| Jun 30, 2023 | 123.72 Mn |
| Mar 31, 2023 | 134.21 Mn |
| Dec 31, 2022 | 150.21 Mn |
| Sep 30, 2022 | 155.99 Mn |
| Jun 30, 2022 | 152.42 Mn |
| Mar 31, 2022 | 69.57 Mn |
| Dec 31, 2021 | 83.41 Mn |
| Sep 30, 2021 | 38.76 Mn |
| Jun 30, 2021 | 42.61 Mn |
| Mar 31, 2021 | 32.93 Mn |
| Dec 31, 2020 | 38.90 Mn |
| Sep 30, 2020 | 7.41 Mn |
| Jun 30, 2020 | 10.97 Mn |
| Mar 31, 2020 | 14.70 Mn |
| Dec 31, 2019 | 20.57 Mn |
| Sep 30, 2019 | 26.57 Mn |
| Jun 30, 2019 | 12.25 Mn |
| Mar 31, 2019 | 15.46 Mn |
| Dec 31, 2018 | 455,662.00 |
| Sep 30, 2018 | 1.07 Mn |
| Jun 30, 2018 | 2.50 Mn |
| Mar 31, 2018 | 5.14 Mn |
| Dec 31, 2017 | 6.32 Mn |
| Sep 30, 2017 | 9.80 Mn |
| Jun 30, 2017 | 10.63 Mn |
| Mar 31, 2017 | 10.80 Mn |
| Dec 31, 2016 | 9.94 Mn |
| Sep 30, 2016 | 10.06 Mn |
| Jun 30, 2016 | 10.90 Mn |
| Mar 31, 2016 | 8.79 Mn |
| Dec 31, 2015 | 8.53 Mn |
| Sep 30, 2015 | 9.17 Mn |
| Jun 30, 2015 | 11.26 Mn |
| Mar 31, 2015 | 12.06 Mn |
| Dec 31, 2014 | 10.72 Mn |
| Sep 30, 2014 | 6.27 Mn |
| Jun 30, 2014 | 7.40 Mn |
| Mar 31, 2014 | 6.27 Mn |
| Dec 31, 2013 | 2.15 Mn |
| Sep 30, 2013 | 863,570.00 |
| Jun 30, 2013 | 1.10 Mn |
| Mar 31, 2013 | 1.57 Mn |
| Sep 30, 2012 | 480.00 |
| Jun 30, 2012 | 1.07 Mn |
| Mar 31, 2012 | 8,888.00 |
| Dec 31, 2011 | 565,789.00 |
| Sep 30, 2011 | 23,478.00 |
| Jun 30, 2011 | 37,030.00 |